Diacylglycerol acyltransferase 2 inhibitors

Patent metadata

Field	Value
Publication number	US-9789110-B2
Application number	US-201615193440-A
Country	US
Kind code	B2
Filing date	Jun 27, 2016
Priority date	Mar 17, 2014
Publication date	Oct 17, 2017
Grant date	Oct 17, 2017

Abstract

Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

First claim

What is claimed is:

1. A method for treating non-alcoholic steatohepatitis (NASH) in humans comprising the step of administering to a human in need of such treatment a therapeutically effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof.

2. A method for treating non-alcoholic steatohepatitis (NASH) in humans comprising the step of administering to a human in need of such treatment a therapeutically effective amount of a compound comprising 3-((2-(3-(2-ethoxyphenoxy)piperidin-1-yl)pyrimidine-5-carboxamido)methyl)benzoic acid or (R)-3-((2-(3-(2-ethoxyphenoxy)piperidin-1-yl)pyrimidine-5-carboxamido)methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

3. The method according to claim 1 wherein said compound or pharmaceutically acceptable salt thereof is in admixture with at least one pharmaceutically acceptable excipient.

4. The method according to claim 2 wherein said compound or pharmaceutically acceptable salt thereof is in admixture with at least one pharmaceutically acceptable excipient.

Assignees

• Pfizer

Inventors

• Futatsugi Kentaro

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title